For a fatal or life-threatening ADR, the initial notification must include which of the following elements?

• A. Only patient initials and the medication name.
• B. Laboratory values only.
• C. Unrelated demographic data.
• D. An assessment of the importance and implication of the findings, including prior experience.

Answer: (D)

When a fatal or life-threatening adverse drug reaction occurs, the initial notification must convey how serious the finding is and what it implies for patient safety and the trial. Including an assessment of the importance and implications of the finding, and referring to prior experience with similar events, provides essential context to determine causality, risk, and immediate safety actions. This helps sponsors and regulators understand the significance beyond the raw data and decide on necessary steps to protect participants. Merely listing identifiers or the drug name, or presenting laboratory values alone, or including unrelated demographics does not give that urgent, interpretive context.